Consensus
The community sees this as very unlikely for Novartis at 15%, based on 8 forecasts. Forecasters are in moderate agreement.
Resolves YES if Novartis is down more than 18% 180 days out versus its baseline price.
Share your read on this question — the best forecasters show their work.
See the whole nvs discussion →